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Liver fat accumulation generally related to systemic insulin resistance characterizes nonalcoholic fatty liver disease (NAFLD),
which in the presence of nonalcoholic steatohepatitis (NASH) can progress towards cirrhosis and hepatocellular carcinoma. Due
to the epidemic of obesity, NAFLD is now the most frequent liver disease inWestern countries. Epidemiological, familial, and twin
studies provide evidence for a strong genetic component of NAFLD susceptibility. Recently, genome-wide association studies led
to the identification of the major inherited determinants of hepatic fat accumulation: patatin-like phospholipase domain-containing
3 (PNPLA3) I148M gene and transmembrane 6 superfamily member 2 (TM6SF2) E167K gene variants, involved in lipid droplets
remodelling and very low-density lipoproteins secretion, are themajor determinants of interindividual differences in liver steatosis,
and susceptibility to progressiveNASH. In this review,we aimed to provide an overview of recent insights into the genetics of hepatic
fat accumulation and steatohepatitis.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is defined by liver
fat deposition in the absence of excessive alcohol intake.
NAFLD is frequently present in obese individuals and it is
also related to metabolic changes such as systemic insulin
resistance [1]. In susceptible individuals, hepatic steatosis
may result in oxidative hepatocellular damage, inflammation,
and activation of fibrogenesis, namely, nonalcoholic steato-
hepatitis (NASH) [2]. This condition potentially progresses
towards liver cirrhosis and hepatocellular carcinoma [3]. Due
to the epidemic of obesity and the advances in the prevention
and treatment of viral hepatitis NAFLD is now the most
frequent liver disease and the leading cause of altered liver
enzymes in Western countries [4, 5]. Subsequently, NASH
will become the leading cause of end-stage liver disease,
liver transplantation, and hepatocellular carcinoma within
the next decades.
Epidemiological, familial, and twin studies provide evi-
dence for heritability of hepatic fat content,NAFLD, and bona
fide metabolic cirrhosis [6, 7]. In the last years, the genetic
determinants of steatosis are being unrevealed using genome-
wide association studies. These studies have identified
patatin-like phospholipase domain-containing 3 (PNPLA3)
gene variant, involved in hepatocellular lipid droplets remod-
elling and very low-density lipoprotein (VLDL) secretion, as
a major determinant of interindividual and ethnicity-related
differences in hepatic fat content [8, 9]. The transmembrane
6 superfamily member 2 (TM6SF2) E167K gene variant, inter-
fering withVLDL secretion, whichmay be stimulated in early
NAFLD [10], has recently been shown to increase suscepti-
bility to progressive NASH by compartmentalization of lipids
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within hepatocytes [11, 12]. Furthermore, case-control studies
demonstrated a role of other genetic variants implicated in
inflammation [13], insulin signaling [14], oxidative stress, iron
metabolism [15–18], and fibrogenesis [19] in the progression
of fatty liver towards NASH associated fibrosis.
Newly identified genetic risk variants could provide a
useful tool for the clinical management and prognosis of
patients withNAFLD.Theymay also lead to the identification
of drugs for treating NASH, a condition for which specific
pharmacological treatment is still lacking.
The main purpose of this narrative review is to provide
an overview of recent insights into the genetics of hepatic
fat accumulation and steatohepatitis, specifically focusing
on inherited variants regulating lipid metabolism. These
recent advances have contributed in a short time to unravel
the pathogenesis of NAFLD and may soon translate into
therapeutic advances. For a comprehensive overview of all
studies related to NAFLD and NASH genetics see the recent
review by our group [20].
2. Pathophysiology of NAFLD and NASH:
The Current View
TheacronymNAFLDdefines a wide spectrumof liver disease
characterized by hepatic fat accumulation in the form of
triglycerides exceeding 5% of liver mass in the absence
of significant alcohol consumption. NAFLD may remain
uncomplicated or progress into severe hepatitis characterized
by severe steatosis, lobular inflammation, and hepatocellular
damage and apoptosis with activation of fibrogenesis [21].
The final outcome of NAFLD is life threatening conditions,
namely, cirrhosis and hepatocellular carcinoma [3]. Hep-
atic fat accumulation results from an unbalance between
triglycerides acquisition, synthesis, utilization, and secretion
[22, 23] and it represents the safest way to store fatty acids
(FFAs) in the liver [24]. Several lines of evidence support a
model where the excess in hepatocellular triglycerides derives
from increased peripheral lipolysis [25] due to adipose
tissue insulin resistance [26], an increased hepatic lipogen-
esis due to hyperinsulinemia, and an excessive food intake
(Figure 1(a)). Indeed, the major determinant of NAFLD is
systemic insulin resistance [1, 27]. Steatosis per se may then
in turn worsen hepatic insulin resistance contributing to
metabolic disturbances and cardiovascular damage [28, 29].
Reduction in hepatocellular triglycerides secretion through
VLDL [23] and in utilization due to mitochondrial damage is
also involved in hepatic fat accumulation.
The development of NASH has been classically ascribed
to the occurrence of multiple parallel “second-hits,” leading
to the activation of inflammation, in the context of hepatic
steatosis [30, 31]. This second insult may be related to
a variety of conditions: (a) direct hepatic lipotoxicity, (b)
hepatocellular oxidative stress secondary to free radicals
producedduring𝛽- and omega-oxidation of FFAs, (c) inflam-
mation triggered by endotoxin engaging Toll-like receptor-4
in Kupffer cells and hepatocytes due to increased intestinal
permeability, (d) qualitative and quantitative changes in gut
microbiota [32–34], (e) release of cytokines by the hepatic
stellate cells, and (f) endoplasmic reticulum stress. All these
conditions lead in the end to inflammation, cellular damage,
and activation of fibrogenesis in the liver [35].
3. Heritability of NAFLD and NASH
Epidemiological, familial, and twin studies [6, 7] and clinical
case series showing familial clustering support a strong
heritability component in NAFLD and NASH [36]. Twin
studies show that ALT levels, mostly reflecting liver fat
content in the absence of alcohol abuse or viral hepatitis, are
a heritable trait explained up to 60% by genetic factors [37]. A
study population among Danish twins identified substantial
heritability (35–61%) for levels of aminotransferases [38].
Ethnic differences have been reported in the prevalence of
NAFLD and NASH [4, 39]. Hispanics are at higher risk than
individuals of European descent, whereas those fromAfrican
descent are protected from these conditions irrespective of
diabetes and excess body weight [7, 40].
4. PNPLA3 I148M Mutation Is the Major
Genetic Determinant of NAFLD and NASH
The major determinant of the interindividual and ethnicity-
related differences in hepatic fat content was identified by
an exome wide association study. This is the rs738409 C>G
single nucleotide polymorphism (SNP) in the PNPLA3 gene,
encoding for the isoleucine to methionine substitution at
position 148 (I148M) [8]. In humans PNPLA3, also called
adiponutrin, encodes a 481 amino acid membrane protein
localized in the endoplasmic reticulum and at the surface
of lipid droplets. In human this protein has the highest
expression in hepatic stellate cells, retina, and hepatocytes.
In mice Pnpla3 is upregulated in the liver after feeding and
during insulin resistance by fatty acids and the master regu-
lator of lipogenesis SREBP-1c [41]. Although the mechanism
underlying the progression to liver disease remains an area
of active research, PNPLA3 has a triglyceride and retinyl-
palmitate esterase activity [42–44].The isoleucine to methio-
nine substitution leads to a loss of function of these activities,
of the enzyme, leading to changes in an impairment of lipid
catabolism, lipid droplets remodelling, and VLDL secretions
[42, 45, 46]. This would favour hepatocellular accumulation
of triglycerides during insulin resistance (Figure 1(b)).
A robust association of the I148M variant with hepatic fat
content has been confirmed in several studies both in adults
[8, 47–58] and in developmental age [59–62]. Most impor-
tantly, in carriers of the I148Mmutant protein environmental
stressors, namely, obesity [63], abdominal fat [64, 65], exces-
sive alcohol consumption [66], chronic viral hepatitis [67,
68], or iron overload [69], trigger progressive liver damage
[58]. Dietary habits are also relevant; indeed, the magnitude
of the increase in liver enzymes in I148M carriers is correlated
to high dietary carbohydrate and sugar consumption [70–72]
and increased omega6/omega3 polyunsaturated fatty acids
ratio [73, 74]. Interestingly, the carriers of the PNPLA3 I148M
variant have a substantial increased risk in cirrhosis and
hepatocellular carcinoma [66, 67, 75–84] independently of
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Figure 1: Molecular genetics of NASH. (a) NAFLD is characterized by the hepatic fat accumulation in lipid droplets resulting from an
unbalance between triglycerides acquisition and secretion. FFA stored as triglycerides during hepatic steatosis derive fromperipheral lipolysis
related to adipose tissue insulin resistance, followed by de novo lipogenesis induced by hyperinsulinemia, and excessive food intake. In the
liver, FFA can be catabolized through 𝛽-oxidation and reesterification to triglycerides and stored as lipid droplets or exported as VLDL. (b)
PNPLA3 I148M variant is attached on the surface of lipid droplets reducing triglyceride breakdown leading to lipid retention in the hepatocyte
lipid droplet. (c) TM6SF2 E167K variant reduces triglycerides secretion through VLDL, leading to hepatocellular retention of lipids.
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the predisposition to steatosis. This suggests that PNPLA3
contributes directly to the fibrogenesis and carcinogenesis
[9, 57, 61, 83, 85]. Indeed, PNPLA3 retinyl-palmitate activity
in hepatic stellate cells may influence hepatic regeneration
and differentiation by altering availability of retinol, potent
regulators of these phenomena [44].
To summarize the PNPLA3 I148M variant is a robust
genetic determinant of hepatic steatosis triggered by a
number of environmental factors [9, 85] and the PNPLA3
associated steatohepatitis (PASH) may be mediated by a
direct effect on hepatocyte and on hepatic stellate cells
[86]. The mechanisms linking the I148M PNPLA3 variant
with liver disease progression and hepatocellular carcinoma
development have recently been reviewed by our group [9,
83].
5. TM6SF2 E167K and Very Low-Density
Lipoproteins Secretion
In 2014, two exome and genomewide association studieswere
reported identifying the rs58542926 C > T genetic variant of
the transmembrane 6 superfamily member 2 gene (TM6SF2),
which encodes the loss-of-function lysine (E) to glutamic acid
(K) at position 167 substitution (E167K), as a determinant
of hepatic triglyceride content, serum aminotransferases,
and lower serum lipoproteins [11, 87]. The same studies
demonstrated that silencing of TM6SF2 reduces secretion of
VLDL resulting in intrahepatic retention of triglycerides and
steatosis in mice and in hepatocytes in vitro [11, 87, 88].
Very recently, in large collaborative European study
evaluating a large cross-sectional cohort of 1,201 individuals
at risk of NASH it was demonstrated that the E167K variant is
associated with the full spectrum of liver damage associated
with hepatic fat accumulation, including NASH, hepatocel-
lular ballooning, and necroinflammation. Importantly, the
association between the E167K variant and advanced fibrosis
was abolished after conditioning for NASH, suggesting that
fibrosis progression is mediated by the effect of the genetic
variant on intracellular retention of lipids, mainly triglyc-
erides and cholesterol, within hepatocytes. In keeping with
this interpretation, the severity of liver damage was found
to be correlated with the amount of hepatic triglycerides
accumulation in patients with NAFLD [89].
The link between the NCAN locus and NAFLD severity
[90, 91] and an independent study reporting an association
between TM6SF2 and moderate/severe fibrosis [92] sup-
port the association between TM6SF2 and liver damage in
NAFLD. Indeed, the E167K is the causal variant explain-
ing the association of the NCAN locus with altered lipid
metabolism [11, 87].
The association of E167K with NASH and advanced
fibrosis contradicts the notion that long-term storage of
fatty acids in hepatocytes in triglycerides is benign [93]. In
addition, it has been demonstrated that also the PNPLA3
I148M variant by altering lipid droplets remodelling impairs
the ability to export triglycerides to secreted VLDL [45,
46]. The deleterious effect on liver damage of the impaired
ability to secrete triglycerides in VLDL is also supported by
the association between progressive liver disease and rare
apolipoprotein B (APOB) andmicrosomal triglyceride transfer
protein (MTTP) mutations directly causing VLDL retention
[93, 94]. A possible alternative mechanism may be related
to the toxicity of excessive hepatocellular cholesterol and the
consequent mitochondrial damage in carriers of the E167K
variant [95, 96]. All in all, these novel findings suggest that
compartmentalization of neutral lipids within hepatocytes is
harmful for the liver.
6. GCKR and Lipogenesis
In a meta-analysis of combined GWAS datasets, besides
PNPLA3 I148M, other genetic loci were associated with liver
fat content. These included NCAN (explained by TM6SF2,
as mentioned previously), glucokinase regulator (GCKR,
SNP rs780094), and lysophospholipase-like 1 (LYPLAL1, SNP
rs12137855). Both variants in GCKR, a regulator of glu-
cose metabolism and LYPLAL1, involved in triglycerides
catabolism, were also shown to influence liver damage [97,
98]. It has been hypothesized that the association of the
rs780094 GCKR polymorphism with hepatic fat accumula-
tion can be explained by the linkage disequilibrium with
rs1260326, encoding for the P446L protein variant. The
P446L variant indeed affects GCKR ability to negatively
regulate glucokinase in response to fructose-6-phosphate,
thereby determining constitutive activation of hepatic glu-
cose uptake [99]. This would lead to decreased circulating
fasting glucose and insulin levels, but on the other hand
it would lead to increased glycolysis and production of
malonyl-CoA. Malonyl-CoA is a key metabolite, because it
favors hepatic fat accumulation by serving as a substrate
for lipogenesis and blocks fatty acid oxidation through the
inhibition of carnitine-palmitoyl transferase-1.The combined
effects of PNPLA3 I148M and GCKR P446L polymorphisms
explained up to one-third of variability in liver fat content
in a recently reported series of obese children [100, 101]. All
this body of evidence shows that genetic variants influencing
hepatocellular lipid accumulation predispose both to fatty
liver and to progressive NASH.
7. Other Variants Regulating
Lipid Metabolism
According to the aforementioned hypothesis, other genes
involved in hepatic fat uptake, synthesis, storage, and mobi-
lization are therefore candidates to influence the develop-
ment and progression of NAFLD. Among these are vari-
ants in peroxisome proliferator-activated nuclear receptors
(PPAR). PPAR𝛼, a molecular target of long chain fatty acids,
eicosanoids, and fibrates [102], is highly expressed in tissues
that catabolize fatty acids such as the liver, where, under
condition of increased hepatic fatty acid influx or decreased
fatty acid efflux, PPAR𝛼 activation prevents the accumulation
of triglycerides by increasing the rate of fatty acid catabolism.
However, the Leu162Val loss-of-function PPAR𝛼 variant did
not influence the risk of NAFLD and the severity of liver
disease [103, 104].
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PPAR𝛾 is highly expressed in adipose tissue and regulates
adipocyte differentiation, FFA uptake, and storage. Pharma-
cological activation of PPAR𝛾 improves insulin resistance in
diabetes and decreases steatosis in NAFLD patients by restor-
ing adipose tissue insulin sensitivity and adiponectin release
[105, 106]. The Pro12Ala loss-of-function SNP in PPAR𝛾2,
inducing a modest impairment of transcriptional activity
due to decreased DNA-binding affinity, was associated with
a reduction of PPAR𝛾 activity in adipose tissue as well
as decreased insulin resistance [107]. However, inconsistent
results have been reported concerning the association of this
variant with the severity of liver damage inNAFLD [103, 104].
Another interesting candidate is represented by Lipin1
(LPIN1), a phosphatidate phosphatase that is highly expressed
in the liver and adipose tissue, and is involved in the
synthesis of phospholipids downstream of the step catalysed
by PNPLA3 [108] and of triglycerides. LPIN1 is required
for adipogenesis and the normal metabolic flux between
adipose tissue and liver, where it also acts as an inducible
transcriptional coactivator to regulate fatty acid metabolism
[56]. LPIN1 variants have been associated with several com-
ponents of the metabolic syndrome, including body mass,
insulin levels, resting metabolic rate, and responsiveness to
insulin sensitizers [109, 110]. In a pediatric population, LPIN1
rs13412852 TT genotype was protective towards NAFLD
[111]. Although independent validation of these results is
required, these data suggest that LPIN1 variants predispose
to progressive NASH at early age by influencing lipogenesis
and lipid metabolism.
Fatty acid transport proteins (FATP) hold a crucial role
in mediating cellular FFA uptake. In the liver FATP2 and
FATP5 are predominantly expressed [112]. FATP5 encodes
a multifunctional protein which increases the hepatic FFA
uptake and activates very long-chain fatty acids and has bile-
CoA ligase activity [113, 114]. FATP5 silencing reversed diet-
induced NAFLD and improved hyperglycemia in mice [115].
Interestingly, the rs56225452 FATP5 promoter variant linked
to transcriptional activity has been associated with ALT levels
in a population study and with steatosis severity in NAFLD
patients [116].
Interestingly, a genetic variant in the promoter region
regulating the expression of uncoupling protein 2 (UCP2) has
recently been associated with altered lipoprotein metabolism
and reduced susceptibility to NASH [117]. Besides regulating
mitochondrial redox status and energy dissipation, UCP2 is
involved in the export of fatty acids from mitochondria in
hepatocytes and is induced during steatosis. It is therefore
possible that it may modulate the risk of NASH by altering
mitochondrial fluxes of lipids during NAFLD.
Apolipoprotein C3 (APOC3) is a major constituent of
VLDL, chylomicrons, and HDL cholesterol, which inhibits
lipoprotein lipase and triglyceride clearance [118]. Petersen
et al. reported that two common APOC3 T-455C and C-
482T promoter variants predispose to liver fat accumulation
in Indian individuals. However, these data have not been
confirmed in large population studies and in other ethnic
groups. Furthermore, APOC3 variants were not associated
with the histological severity of liver damage in NAFLD
[119–121]. These data suggest that genetic factors influencing
triglyceride metabolism outside the liver are not involved in
the pathogenesis of progressive NAFLD.
8. Other Variants Not Implicated in
Lipid Metabolism
Although recent genetic evidence concordantly points to a
major role of variants influencing intrahepatocellular lipid
metabolism in the pathogenesis of NAFLD and progres-
sive NASH, as recently reviewed by our group [20], other
genetic variants may be implicated in the progression of liver
disease.
The most solid associations have been collected for
genetic variants involved in the regulation of inflammation,
such as TNFalpha and IL28B polymorphisms [13, 122],
oxidative stress [13, 122], iron metabolism [15, 17, 18], which
is frequently altered in NAFLD [124], and fibrogenesis [19].
However, the overall evidence supporting these associations
is weaker than that already obtained for the PNPLA3 I148M
andTM6SF2 E167K genetic variants, as these results still need
independent validation in independent cohorts.
9. Conclusions
Genes play a key role in the susceptibility and progression
of NAFLD. To date, the PNPLA3 I148M and TM6SF2 E167K
gene variants are the major determinants of interindividual
differences in liver steatosis and susceptibility to progressive
NASH. Both of these genes determine liver fat retention
through lipid droplets and very low-density lipoproteins
modifications. PNPLA3 affects also directly hepatic stellate
cells and retinol metabolism. These novel findings suggest
that hepatocellular accumulation of neutral lipids is harmful
for the liver. Several other genetic variants, including rare
mutations, involved in the regulation of hepatocellular lipid
metabolism, are being scrutinized.
Future challenges will be (a) to understand the molec-
ular mechanisms underlying the association between gene
variants and progressive liver disease, (b) to evaluate the
impact of gene variants in the clinical practice to stratify
individual risk, and (c) to examine pharmacogenetic response
to available therapies. This knowledge will offer insights
into pathogenesis of NASH and importantly suggest novel
therapeutic targets.
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